Crown Bioscience Introduces New Recombinant Cell Lines for Oncology Drug Discovery

(Santa Clara, Calif., June 30, 2016) — Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, is announcing the launch of six new recombinant cell lines for biological studies and drug screening, discovery and development.

CrownBio’s new stable cell lines, with CD137, CTLA-4, GITR, ICOS, OX40 and RANK immune checkpoints and receptors, are important targets and pathways for oncology drug discovery and development. These cell lines join CrownBio’s robust life science portfolio, including a Wnt Luciferase reporter as well as ALK Kinases, BCR-ABL Kinase, EGFR, PD-1 and PD-L1 cell lines, for a total of 16 off-the-shelf recombinant cell lines available for purchase.

“We are excited to be offering these new cell lines to researchers and drug development scientists,” said Abe Couse, vice president of the life science division at CrownBio. “These recombinant cell lines express enzymes and proteins that can impact immune response, cell proliferation and cell death, and they will help scientists better understand the role of these genes and related pathways to the causes and potential cures for cancer.”

CrownBio is releasing the cell lines in combination with the company’s recently launchedin vivo grade isotype controls and diabetic and cancer tissue samples from relevant models. With affordable prices and proven quality, CrownBio has made the stable cell lines available for delivery, ready to be shipped overnight for next day delivery in the United States and within one week internationally.

“These cell lines provide ‘gold standard’ services and tools to our clients within preclinical drug discovery,” said Jean-Pierre Wery, Ph.D., president at CrownBio. “Ultimately, we hope to reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic.”

For more information on CrownBio’s existing and new cell lines, visitwww.crownbio.com.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.